• Novartis focusing on cutting CAR-T costs ahead of EU launches pharmaphorum
    November 26, 2018
    Novartis is focusing on cutting manufacturing costs for its CAR-T cancer cell therapy as the company launches it across Europe, while keeping a watching brief on ‘off-the-shelf’ therapies that could potentially be cheaper to produce.
PharmaSources Customer Service